Abstract: This invention relates to a method for the isolation of a target nucleic acid using a material with an unmodified silica surface and subsequent amplification of the target nucleic acid in the presence of the material with an unmodified silica surface. The method is preferably carried out as an automated process preferably in a high throughput format. The method is preferably used in diagnostics.

Abstract: Method for the detection of a nucleic acid comprising the production of a plurality of amplificates of a section of this nucleic acid with the aid of two primers, one of which can bind to a binding sequence A of the nucleic acid and the other can bind to a binding sequence C? which is complementary to a sequence C which is located in the 3? direction from A and does not overlap with A, contacting the amplificates with a probe having a binding sequence D which can bind to a sequence B which is located between the sequences A and C or to the complement thereof, and detecting the formation of a hybrid of the amplificate and probe where the sequence located between the binding sequences A and C contains no nucleotides that do not belong to the binding sequence D of the probe or its complement D?.

Abstract: This invention relates to a method for the isolation of a target nucleic acid using a material with an unmodified silica surface and subsequent amplification of the target nucleic acid in the presence of the material with an unmodified silica surface. The method is preferably carried out as an automated process preferably in a high throughput format. The method is preferably used in diagnostics.

Abstract: Method for the detection of a nucleic acid comprising the production of a plurality of amplificates of a section of this nucleic acid with the aid of two primers, one of which can bind to a binding sequence A of the nucleic acid and the other can bind to a binding sequence C′ which is complementary to a sequence C which is located in the 3′ direction from A and does not overlap with A, contacting the amplificates with a probe having a binding sequence D which can bind to a sequence B which is located between the sequences A and C or to the complement thereof, and detecting the formation of a hybrid of the amplificate and probe where the sequence located between the binding sequences A and C contains no nucleotides that do not belong to the binding sequence D of the probe or its complement D′.

Abstract: The present invention provides a dry reagent for blood coagulation tests in which an at least partial course of the coagulation cascade takes place, comprising a carrier material which contains a chromophoric substrate of a protease of the blood coagulation system, at least one factor and/or co-factor of the blood coagulation system and a buffer.

Abstract: The present invention provides a process for the photometric determination of protein C and/or protein S activity, especially in plasma, wherein the sample containing the protein C and/or protein S to be determined is incubated with a protein C activator from snake venom with the formation of activated protein C and/or protein S and the decrease of the formation of thrombin from prothrombin brought about by the coagulation factors and the activators thereof is determined by means of a chromogenic thrombin substrate.

Abstract: The present invention provides a process for stabilizing creatine kinase by disulphide modification, wherein creatine kinase is reacted in any desired sequence(a) with a molar excess of disulphide and/or thiosulphonate and(b) with a molar excess of water-soluble carbohydrate as carrier.

Abstract: The present invention provides an analysis element for the determination of coagulation parameters with the help of a detectable or a detection reaction-initiating substrate of a protease of the blood coagulation system and at least one factor and/or co-factor of the blood coagulation system and a buffer substance, wherein the factor and/or co-factor, together with a water-soluble, non-ionic polymer which does not falsely influence the course of the coagulation cascade, is impregnated on an open, planar composite structure which consists of a material which does not have a disturbing influence on the course of the coagulation.

Abstract: The present invention provides a process for the photometric determination of prekallikrein in plasma, wherein plasma is incubated with a surface activator, the extinction obtained is measured, a chromogenic thrombin substrate is then added thereto, the optically determinable group liberated therefrom is measured at short time intervals or continuously and the gradient of the linear part of the curve obtained by plotting the time against the extinction is determined as a measure of the prekallikrein content. The partial thromboplastin time of plasma is simultaneously determined by carrying out the incubation in the presence of calcium ions and a phospholipid and measuring the time it takes the extinction to reach a predetermined level.

Abstract: The present invention provides a process for the determination of fibrin monomer in plasma, wherein a plasma sample containing fibrin monomer and freed from plasmin inhibitors is incubated in buffered solution with tissue plasminogen activator (EPA), plasminogen and a chromogenic plasmin substrate and the color formed is measured as a measure of the amount of fibrin monomer.The present invention also provides a reagent for the determination of fibrin monomer in plasma, wherein it contains plasminogen, tissue plasminogen activator (EPA), chromogenic plasmin substrate and buffer (pH 7.0 to 9.0).

Abstract: The present invention provides a control or calibration serum for lipid diagnosis, wherein it contains the parameters relevant for lipid diagnosis in the normal or pathological concentration range in a single storage-stable form.The present invention also provides processes for the preparation of this control or calibration serum.

Abstract: The present invention provides a process for the specific determination of the cholesterol of the LDL fraction in the presence of the HDL fraction of the lipoproteins of serum by the action of cholesterol esterase for the liberation of the cholesterol and oxidation of the liberated cholesterol with cholesterol oxidase and oxygen with the formation of hydrogen peroxide and cholestenone and kinetic measurement of the change of one of the reaction components of the oxidase reaction, especially the formation of hydrogen peroxide, wherein the measurement is carried out in a predetermined period of time, the reaction solution having a tenside concentration of 0.01 to 1.5 mmol/liter, a cholesterol esterase concentration of 0.1 to 30 U/ml. and a pH value of 6.5 to 8.0.The present invention also provides a reagent for carrying out this process.

Abstract: The present invention provides a process for the direct turbidimetric determination of .beta.-lipoproteins (LDL) in body fluids by precipitation with polyanions and divalent cations, wherein the precipitation is carried out in the presence of a complex former at a pH value of from 7 to 9.The present invention also provides a reagent for the direct turbidimetric determination of .beta.-lipoproteins (LDL) in body fluids, comprising a polyanion, a salt of a divalent metal, a complex former and a substance buffering at pH 7 to 9.

Abstract: Method and reagent for the determination of the biological activity of heparin in plasma by adding thrombin or Factor X.sub.a as the proteolytic enzyme and a chromogen substrate of the latter and measuring the dye liberated from the chromogen substrate in the absence of exogenous anti-thrombin III, the improvement consisting of adding, additionally, at least one compound of the formula ##STR1## wherein X is oxygen or the group NR.sub.5 ;and R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are independently selected from hydrogen or alkyl of 1 to 2 carbon atoms.

Abstract: The present invention provides a stabilized thrombin preparation in solid or dissolved form, especially for analytical purposes, containing, as a stabilizer, serum albumin together with at least one protease inhibitor and at least one chelate former.

Abstract: For the determination of glycerol, the latter is incubated with galactose oxidase in an aqueous medium in the presence of oxygen and either the oxygen consumption or the amount of H.sub.2 O.sub.2 or glyceraldehyde that is formed is determined. A reagent suitable for this purpose consists of galactose oxidase and a system for the determination of H.sub.2 O.sub.2 or a system for the determination of glyceraldehyde. It can additionally contain an agent for the saponification of esterified glycerol.

Abstract: A control reagent for heparin activity determination comprising20 to 1500 USP heparin,2000 to 30000 IU antithrombin III,0.15 to 1.5 millimoles serum albumin,0.005 to 0.05 mole ethylenediaminetetraacetic acid sodium salt,0 to 0.4 mole saccharose,2000 to 20000 U aprotinin, andbuffer substance, pH 6.5 to 7.5,per liter of control reagent solution.

Abstract: A method for determining biologically active heparin comprising adding, in the absence of exogenous antithrombin III, a proteolytic enzyme selected from the group consisting of thrombin and factor Xa and a chromogen substrate for the enzyme to a heparin sample, measuring the dye released from the chromogen substrate and thus determining the amount of heparin present.